ALK-Abelló Feed

2026-11-02 20:55:06 Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer

2026-11-02 20:55:06 Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

2026-10-19 15:29:07 Phase 3 trial in China successfully confirms ACARIZAX® safety and efficacy in patients with house dust mite allergy 237,00 DKK | +4,22% | 93,8 MDKK

2026-10-19 15:29:07 Vellykket fase 3-studie i Kina bekræfter sikkerhed og effekt af ACARIZAX® hos patienter med husstøvmideallergi 237,00 DKK | +4,22% | 93,8 MDKK

2026-10-12 12:05:00 BSACI 2026: New preference and ease-of-use data comparing EURneffy® nasal adrenaline spray and adrenaline auto-injector trainer devices 228,00 DKK | +0,26% | 64,6 MDKK

2026-10-07 19:02:00 ALK upgrades its full-year outlook on strong tablet sales 228,20 DKK | +4,68% | 134 MDKK

2026-10-07 19:02:00 ALK opjusterer forventningerne til 2026 på baggrund af stærkt tabletsalg 228,20 DKK | +4,68% | 134 MDKK

2026-09-30 15:03:23 ALK expands strategic tablet supply partnership with Catalent 198,40 DKK | +1,07% | 39,9 MDKK

2026-09-30 15:03:23 ALK udvider strategisk partnerskab med Catalent om tabletproduktion 198,40 DKK | +1,07% | 39,9 MDKK

2026-09-21 11:00:00 ALK appoints Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy 199,10 DKK | +0,30% | 36,1 MDKK

2026-09-11 13:35:00 ALK to present at the Morgan Stanley Global Healthcare Conference in New York 195,90 DKK | -1,66% | 37,6 MDKK

2026-08-22 12:24:14 Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer

2026-08-22 12:24:14 Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

2026-08-21 14:01:09 Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff 216,00 DKK | +3,35% | 81,0 MDKK

2026-08-21 14:01:09 Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer 216,00 DKK | +3,35% | 81,0 MDKK

2026-08-20 07:33:00 ALK appoints Jacob Glenting as head of Global R&D 209,00 DKK | -6,53% | 138 MDKK

2026-08-20 07:30:00 Six-month interim report (Q2) 2026 (unaudited) - English version only 209,00 DKK | -6,53% | 138 MDKK

2026-08-20 07:30:00 Six-month interim report (Q2) 2026 (unaudited) 209,00 DKK | -6,53% | 138 MDKK

2026-08-14 12:23:36 ALK’s tree pollen and house dust mite tablets now recommended by NICE for paediatric treatment in the UK health system 218,60 DKK | -0,64% | 43,0 MDKK

2026-08-13 16:06:44 Invitation til præsentation af ALK’s regnskab for første halvår (Q2) 2026 torsdag den 20. august 2026 220,00 DKK | -0,99% | 26,6 MDKK

2026-08-13 16:06:44 Invitation to the presentation of ALK’s first six months (Q2) 2026 results on Thursday, 20 August 2026 220,00 DKK | -0,99% | 26,6 MDKK

2026-08-05 13:10:06 Market launch of the nasal adrenaline spray, neffy®, for treatment of adults and children with severe allergies in Canada 221,80 DKK | +1,65% | 48,6 MDKK

2026-06-15 09:00:00 EURneffy 1 mg approved in the UK as the first and only needle-free adrenaline treatment for young children (aged 4 and older, 15–30 kg) at risk of anaphylaxis 269,60 DKK | -0,30% | 40,5 MDKK

2026-06-11 09:00:00 Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap 269,20 DKK | +0,22% | 26,1 MDKK

2026-06-04 08:30:00 ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026 266,20 DKK | +1,53% | 52,4 MDKK

2026-06-01 21:20:29 Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer 261,40 DKK | -0,38% | 31,1 MDKK

2026-06-01 21:20:29 Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff 261,40 DKK | -0,38% | 31,1 MDKK

2026-05-29 16:27:19 ALK to present at the Jefferies Global Healthcare Conference in New York 268,00 DKK | +1,06% | 91,2 MDKK

2026-05-04 12:16:58 Three-month interim report (Q1) 2026 (unaudited) 259,00 DKK | +7,02% | 163 MDKK

2026-05-04 12:16:58 Three-month interim report (Q1) 2026 (unaudited) - English version only 259,00 DKK | +7,02% | 163 MDKK

2026-05-04 12:09:09 ALK opjusterer forventningerne til 2026 259,00 DKK | +7,02% | 163 MDKK

2026-05-04 12:09:09 ALK upgrades its full-year outlook 259,00 DKK | +7,02% | 163 MDKK

2026-04-28 16:14:06 Invitation til præsentation af ALK’s regnskab for første kvartal 2026 tirsdag den 5. maj 2026 234,00 DKK | +2,09% | 56,0 MDKK

2026-04-28 16:14:06 Invitation to the presentation of ALK’s first quarter 2026 results on Tuesday, 5 May 2026 234,00 DKK | +2,09% | 56,0 MDKK

2026-04-20 14:33:27 ALK annoncerer positive fase 2-resultater for tablet til behandling af peanutallergi, som viser tidligt indsættende effekt 223,20 DKK | +5,78% | 106 MDKK

2026-04-20 14:33:27 ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy 223,20 DKK | +5,78% | 106 MDKK

2026-04-15 12:07:36 neffy® approved as the first needle-free anaphylaxis treatment of adults and children in Canada 213,80 DKK | -0,93% | 43,6 MDKK

2026-04-08 22:37:40 Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff 207,60 DKK | +0,48% | 46,5 MDKK

2026-04-08 22:37:40 Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer 207,60 DKK | +0,48% | 46,5 MDKK

2026-04-01 10:05:00 Tildeling af aktiebaserede langsigtede incitamentsinstrumenter til direktion og ledende medarbejdere 205,80 DKK | +1,78% | 42,7 MDKK

2026-04-01 10:05:00 Grant of share-based long-term incentive instruments to members of the Board of Management and key employees 205,80 DKK | +1,78% | 42,7 MDKK

2026-03-31 09:01:00 EURneffy 1 mg approved across the EU as the first and only needle-free adrenaline treatment for young children (≥15 kg) at risk of anaphylaxis 202,20 DKK | +0,60% | 52,2 MDKK

2026-03-16 18:37:39 Generalforsamling i ALK-Abelló A/S afholdt den 16. marts 2026 213,00 DKK | +0,38% | 26,1 MDKK

2026-03-16 18:37:39 Annual General Meeting in ALK-Abelló A/S held on 16 March 2026 213,00 DKK | +0,38% | 26,1 MDKK

2026-03-04 11:20:00 New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors 223,00 DKK | +3,72% | 41,4 MDKK

2026-02-20 14:55:07 Annual General Meeting in ALK-Abelló A/S on 16 March 2026 214,60 DKK | -2,45% | 88,5 MDKK

2026-02-20 14:55:07 Ordinær generalforsamling i ALK-Abelló A/S den 16. marts 2026 214,60 DKK | -2,45% | 88,5 MDKK

2026-02-20 07:32:04 Henriette Mersebach to step down as ALK’s head of R&D 214,60 DKK | -2,45% | 88,5 MDKK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode